vs
Apyx Medical Corp（APYX）与MERIT MEDICAL SYSTEMS INC（MMSI）财务数据对比。点击上方公司名可切换其他公司
MERIT MEDICAL SYSTEMS INC的季度营收约是Apyx Medical Corp的20.6倍（$393.9M vs $19.2M）。MERIT MEDICAL SYSTEMS INC净利率更高（9.6% vs -6.8%，领先16.4%）。Apyx Medical Corp同比增速更快（34.7% vs 10.9%）。MERIT MEDICAL SYSTEMS INC自由现金流更多（$74.0M vs $-2.8M）。过去两年Apyx Medical Corp的营收复合增速更高（36.8% vs 10.3%）
Apyx Medical前身是博维医疗，是美国的医疗器械制造商，专注生产电外科产品与能源技术相关医疗设备，公司总部位于佛罗里达州克利尔沃特，在保加利亚设有生产工厂。
梅里特医疗系统公司是一家全球性医疗设备企业，设计、生产和销售适用于心脏病学、放射学、肿瘤学、内窥镜及重症监护领域的介入和诊断产品，为全球医院及医疗机构提供微创医疗解决方案，助力提升患者疗效和临床操作效率。
APYX vs MMSI — 直观对比
营收规模更大
MMSI
是对方的20.6倍
$19.2M
营收增速更快
APYX
高出23.8%
10.9%
净利率更高
MMSI
高出16.4%
-6.8%
自由现金流更多
MMSI
多$76.9M
$-2.8M
两年增速更快
APYX
近两年复合增速
10.3%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $19.2M | $393.9M |
| 净利润 | $-1.3M | $38.0M |
| 毛利率 | 62.6% | 49.6% |
| 营业利润率 | 0.1% | 13.8% |
| 净利率 | -6.8% | 9.6% |
| 营收同比 | 34.7% | 10.9% |
| 净利润同比 | 71.9% | 36.0% |
| 每股收益（稀释后） | — | $0.64 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APYXMMSI
| Q4 25 | $19.2M | $393.9M | ||
| Q3 25 | $12.9M | $384.2M | ||
| Q2 25 | $11.4M | $382.5M | ||
| Q1 25 | $9.4M | $355.4M | ||
| Q4 24 | $14.2M | $355.2M | ||
| Q3 24 | $11.5M | $339.8M | ||
| Q2 24 | $12.1M | $338.0M | ||
| Q1 24 | $10.2M | $323.5M |
净利润APYXMMSI
| Q4 25 | $-1.3M | $38.0M | ||
| Q3 25 | $-2.0M | $27.8M | ||
| Q2 25 | $-3.8M | $32.6M | ||
| Q1 25 | $-4.2M | $30.1M | ||
| Q4 24 | $-4.6M | $27.9M | ||
| Q3 24 | $-4.7M | $28.4M | ||
| Q2 24 | $-6.6M | $35.7M | ||
| Q1 24 | $-7.6M | $28.2M |
毛利率APYXMMSI
| Q4 25 | 62.6% | 49.6% | ||
| Q3 25 | 64.4% | 48.5% | ||
| Q2 25 | 62.3% | 48.2% | ||
| Q1 25 | 60.1% | 48.4% | ||
| Q4 24 | 63.0% | 48.7% | ||
| Q3 24 | 60.5% | 46.4% | ||
| Q2 24 | 61.7% | 47.7% | ||
| Q1 24 | 58.1% | 46.9% |
营业利润率APYXMMSI
| Q4 25 | 0.1% | 13.8% | ||
| Q3 25 | -6.5% | 11.1% | ||
| Q2 25 | -22.6% | 12.3% | ||
| Q1 25 | -32.4% | 11.5% | ||
| Q4 24 | -21.4% | 10.3% | ||
| Q3 24 | -31.6% | 11.0% | ||
| Q2 24 | -45.7% | 13.6% | ||
| Q1 24 | -64.6% | 11.1% |
净利率APYXMMSI
| Q4 25 | -6.8% | 9.6% | ||
| Q3 25 | -15.4% | 7.2% | ||
| Q2 25 | -33.2% | 8.5% | ||
| Q1 25 | -44.0% | 8.5% | ||
| Q4 24 | -32.5% | 7.9% | ||
| Q3 24 | -40.9% | 8.4% | ||
| Q2 24 | -54.0% | 10.6% | ||
| Q1 24 | -74.0% | 8.7% |
每股收益（稀释后）APYXMMSI
| Q4 25 | — | $0.64 | ||
| Q3 25 | — | $0.46 | ||
| Q2 25 | — | $0.54 | ||
| Q1 25 | — | $0.49 | ||
| Q4 24 | — | $0.46 | ||
| Q3 24 | — | $0.48 | ||
| Q2 24 | $-0.19 | $0.61 | ||
| Q1 24 | $-0.22 | $0.48 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $31.7M | $446.4M |
| 总债务越低越好 | $37.5M | $734.0M |
| 股东权益账面价值 | $14.5M | $1.6B |
| 总资产 | $66.8M | $2.7B |
| 负债/权益比越低杠杆越低 | 2.58× | 0.46× |
8季度趋势，按日历期对齐
现金及短期投资APYXMMSI
| Q4 25 | $31.7M | $446.4M | ||
| Q3 25 | $25.1M | $392.5M | ||
| Q2 25 | $29.3M | $341.8M | ||
| Q1 25 | $31.0M | $395.5M | ||
| Q4 24 | $31.7M | $376.7M | ||
| Q3 24 | $28.0M | $523.1M | ||
| Q2 24 | $32.7M | $636.7M | ||
| Q1 24 | $37.3M | $581.9M |
总债务APYXMMSI
| Q4 25 | $37.5M | $734.0M | ||
| Q3 25 | $37.5M | $732.9M | ||
| Q2 25 | $37.5M | $731.8M | ||
| Q1 25 | $37.5M | $730.7M | ||
| Q4 24 | $37.5M | $729.6M | ||
| Q3 24 | $37.5M | $750.5M | ||
| Q2 24 | — | $801.3M | ||
| Q1 24 | — | $800.1M |
股东权益APYXMMSI
| Q4 25 | $14.5M | $1.6B | ||
| Q3 25 | $5.8M | $1.5B | ||
| Q2 25 | $7.3M | $1.5B | ||
| Q1 25 | $10.5M | $1.4B | ||
| Q4 24 | $14.2M | $1.4B | ||
| Q3 24 | $11.0M | $1.3B | ||
| Q2 24 | $14.7M | $1.3B | ||
| Q1 24 | $20.3M | $1.2B |
总资产APYXMMSI
| Q4 25 | $66.8M | $2.7B | ||
| Q3 25 | $57.4M | $2.6B | ||
| Q2 25 | $58.2M | $2.6B | ||
| Q1 25 | $60.2M | $2.5B | ||
| Q4 24 | $64.8M | $2.4B | ||
| Q3 24 | $60.7M | $2.4B | ||
| Q2 24 | $65.4M | $2.4B | ||
| Q1 24 | $70.7M | $2.3B |
负债/权益比APYXMMSI
| Q4 25 | 2.58× | 0.46× | ||
| Q3 25 | 6.41× | 0.48× | ||
| Q2 25 | 5.17× | 0.49× | ||
| Q1 25 | 3.57× | 0.51× | ||
| Q4 24 | 2.64× | 0.53× | ||
| Q3 24 | 3.40× | 0.57× | ||
| Q2 24 | — | 0.62× | ||
| Q1 24 | — | 0.65× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.5M | $98.5M |
| 自由现金流经营现金流 - 资本支出 | $-2.8M | $74.0M |
| 自由现金流率自由现金流/营收 | -14.6% | 18.8% |
| 资本支出强度资本支出/营收 | 1.4% | 6.2% |
| 现金转化率经营现金流/净利润 | — | 2.59× |
| 过去12个月自由现金流最近4个季度 | $-9.1M | $215.7M |
8季度趋势，按日历期对齐
经营现金流APYXMMSI
| Q4 25 | $-2.5M | $98.5M | ||
| Q3 25 | $-3.5M | $75.0M | ||
| Q2 25 | $-1.2M | $83.3M | ||
| Q1 25 | $-702.0K | $40.6M | ||
| Q4 24 | $-2.9M | $68.7M | ||
| Q3 24 | $-4.4M | $47.3M | ||
| Q2 24 | $-4.3M | $68.5M | ||
| Q1 24 | $-6.3M | $36.2M |
自由现金流APYXMMSI
| Q4 25 | $-2.8M | $74.0M | ||
| Q3 25 | $-4.1M | $52.5M | ||
| Q2 25 | $-1.5M | $69.6M | ||
| Q1 25 | $-757.0K | $19.5M | ||
| Q4 24 | $-3.2M | $65.3M | ||
| Q3 24 | $-4.6M | $38.0M | ||
| Q2 24 | $-4.6M | $57.9M | ||
| Q1 24 | $-6.4M | $24.5M |
自由现金流率APYXMMSI
| Q4 25 | -14.6% | 18.8% | ||
| Q3 25 | -31.5% | 13.7% | ||
| Q2 25 | -13.2% | 18.2% | ||
| Q1 25 | -8.0% | 5.5% | ||
| Q4 24 | -22.4% | 18.4% | ||
| Q3 24 | -40.0% | 11.2% | ||
| Q2 24 | -38.0% | 17.1% | ||
| Q1 24 | -62.2% | 7.6% |
资本支出强度APYXMMSI
| Q4 25 | 1.4% | 6.2% | ||
| Q3 25 | 4.0% | 5.8% | ||
| Q2 25 | 2.3% | 3.6% | ||
| Q1 25 | 0.6% | 5.9% | ||
| Q4 24 | 1.7% | 1.0% | ||
| Q3 24 | 1.3% | 2.8% | ||
| Q2 24 | 2.4% | 3.1% | ||
| Q1 24 | 0.3% | 3.6% |
现金转化率APYXMMSI
| Q4 25 | — | 2.59× | ||
| Q3 25 | — | 2.70× | ||
| Q2 25 | — | 2.56× | ||
| Q1 25 | — | 1.35× | ||
| Q4 24 | — | 2.46× | ||
| Q3 24 | — | 1.66× | ||
| Q2 24 | — | 1.92× | ||
| Q1 24 | — | 1.28× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APYX
暂无分部数据
MMSI
| Other | $154.6M | 39% |
| Peripheral Intervention | $93.2M | 24% |
| Cardiac Intervention | $50.2M | 13% |
| OEM | $42.6M | 11% |
| Custom Procedural Solutions | $33.1M | 8% |
| Endoscopy Segment | $20.1M | 5% |
